4/A: Lifecore Biomedical Director Acquires Shares, Amends Initial Filing

Humberto Calheiros Antunes, a director of Lifecore Biomedical, acquired 24,554 shares of common stock and amended a previous filing to include 3,000 inadvertently omitted shares.

Summary

• On August 19, 2024, Humberto Calheiros Antunes, a director of Lifecore Biomedical, acquired 24,554 shares of the company's common stock.
• The acquisition was reported on a Form 4/A filed with the SEC on September 16, 2024.
• The filing also amended a previous Form 3 filed on August 21, 2024, to include 3,000 shares that were initially omitted.
• Following the reported transaction, Antunes directly owns 27,554 shares of Lifecore Biomedical.
• The acquired securities are restricted stock units that convert into common stock on a 1-for-1 basis.
• These units vest on the earlier of July 8, 2025, or the date of the company's 2025 annual meeting, provided it's at least 50 weeks from July 8, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing about a director's stock transaction. While insider buying can be seen as a positive signal, it's not overwhelmingly positive in this context.

Positives

• A director increasing their stake in the company can be seen as a positive signal.

Industry Context

This filing is a routine disclosure related to insider trading activity, which is common among publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder confidence.

Key Dates